

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
03 October 2019 (03.10.2019)



(10) International Publication Number
WO 2019/191008 A1

(51) International Patent Classification:

A61K 31/437 (2006.01) C07D 401/14 (2006.01)
A61K 31/444 (2006.01) C07D 471/04 (2006.01)
C07D 401/12 (2006.01) A61P 25/06 (2006.01)

(21) International Application Number:

PCT/US2019/023940

(22) International Filing Date:

25 March 2019 (25.03.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/647,794	25 March 2018 (25.03.2018)	US
62/664,761	30 April 2018 (30.04.2018)	US
62/774,285	02 December 2018 (02.12.2018)	US
62/777,180	09 December 2018 (09.12.2018)	US
62/777,625	10 December 2018 (10.12.2018)	US

(71) Applicant: **BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.** [US/US]; 215 Church Street, New Haven, Connecticut 06510 (US).

(72) Inventors: **CORIC, Vladimir**; 215 Church Street, New Haven, Connecticut 06510 (US). **CROOP, Robert**; 215 Church Street, New Haven, Connecticut 06510 (US).

(74) Agent: **VOLLES, Warren** et al.; P.O. Box 689, 67 Sterling Hill Road, Old Lyme, Connecticut 06371 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: RIMEGEPANT FOR CGRP RELATED DISORDERS




Figure 1

(57) Abstract: Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*